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The physiology of age-related functional decline is poorly un-
derstood, but may involve hormones and inflammation. We
hypothesized that older women with both low IGF-I and high
IL-6 levels are at high risk for disability and death. We as-
sessed walking speed and disability in 718 women enrolled in
the Women’s Health and Aging Study I, a 3-yr cohort study
with 5-yr mortality follow-up. Women with IGF-I levels in the
lowest quartile and IL-6 levels in the highest quartile had
significantly greater limitation in walking and disability in
mobility tasks and instrumental activities of daily living than
those with neither risk factor (adjusted odds ratios, 10.77, 5.14,
and 3.66). Women with both risk factors were at greater risk
for death (adjusted relative risk, 2.10) as well as incident walk-
ing limitation, mobility disability, and disability in activities
of daily living compared with those with high IGF-I and low
IL-6 levels.
The combination of low IGF-I and high IL-6 levels confers
a high risk for progressive disability and death in older
women, suggesting an aggregate effect of dysregulation in
endocrine and immune systems. The joint effects of IGF-I and
IL-6 may be important targets for treatments to prevent or
minimize disability associated with aging. (J Clin Endocrinol
Metab 88: 2019–2025, 2003)
GREATER NUMBERS OF individuals are living to olderages, with the prediction that by 2030, 20% of all
Americans, 70 million in number, will be over the age of 65
yr (1). A major concern at the individual and population
levels is how to live these years at a high functional level.
Over one third of those over 65 yr and almost three fourths
of those over the age of 80 yr report at least one severe
disability (2). If we had physiological markers to identify
those at risk for progressive functional decline and impend-
ing death, therapies could be targeted toward these individ-
uals to prevent adverse outcomes.
Alterations in hormonal axes and inflammation pathways
occur with age and have been proposed as critical, indepen-
dent mediators of functional decline in older individuals.
IGF-I has been found to decline with normal aging based on
cross-sectional studies that included healthy, community-
dwelling older people (3–9). Although the GH/IGF-I axis
may mediate alterations in muscle mass and strength, the
functional significance of the IGF-I level in older individuals
is poorly understood. We have previously shown that low
IGF-I levels are associated with slow walking speed and
difficulty with mobility tasks (10), although others have not
seen an association with poor physical function or disability
(11, 12).
IL-6 is a proinflammatory cytokine with both immuno-
logical and nonimmunological roles. Although its produc-
tion is tightly regulated at young ages, the serum concen-
tration tends to increase with age, even in subjects free of
acute or chronic inflammatory diseases (13). Several studies
have shown cross-sectional and prospective associations of
high IL-6 levels with functional disability and mortality (14–
18). Furthermore, there is scientific evidence in model sys-
tems and in humans that high levels of IL-6 decrease IGF-I
and that low levels of IGF-I stimulate IL-6, suggesting a
biological link between IGF-I and IL-6 (19–21).
Given the prior work demonstrating individual detrimen-
tal effects and the plausibility of additive effects of dysregu-
lation in multiple systems, we sought to examine the inde-
pendent and combined effects of alterations of both IGF-I and
IL-6 in a cohort of disabled women over the age of 65 yr. We
hypothesized that women in the lowest quartile of IGF-I and
the highest quartile of IL-6 levels at baseline in the Women’s
Health and Aging Study I (WHAS I) would be at the highest
risk of disability and death compared with those with only
one risk factor or neither.
Subjects and Methods
Study population
WHAS I is a study of the causes and course of disability among
moderately to severely disabled older women living in the community.
The study design was described in detail previously (22, 23). Briefly, a
random sample of 6521 community-dwelling women 65 yr of age or
older was selected from the Health Care Financing Administration’s
Abbreviations: ADL, Activities of daily living; BMI, body mass index;
CI, 95% confidence interval; IADL, instrumental activities of daily living;
OR, odds ratio; RR, relative risk; WHAS I, Women’s Health and Aging
Study I.
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Medicare eligibility list for Baltimore, Maryland. Women who reported
difficulty with 1 or more tasks in 2 or more of 4 domains of functioning
(mobility/exercise tolerance, upper extremity activities, basic self-care,
and household management tasks) and who had a Mini Mental State
score of 18 or greater were considered eligible for the study. Seventy-one
percent (n  1002) of those eligible (n  1409) agreed to participate. The
Johns Hopkins University institutional review board approved the
study, and all participants gave informed consent.
Questionnaires and examinations were performed in the participant’s
home at 6-month intervals over 3 yr beginning in 1992, for a total of 7
visits. Baseline blood samples were obtained within 90 d of 1 of the first
3 examinations in 718 subjects, processed, placed on ice, and sent the
same day to Quest Diagnostics, Inc. (Tetorboro, NJ). Samples were also
processed to obtain aliquots of serum that were stored at –80 C. Par-
ticipants who did not provide blood samples were older and had more
disability in activities of daily living, but were not different in body mass
index (BMI) or number of chronic diseases.
Assessment of biochemical measures
IGF-I was measured by RIA with ethanol extraction (Nichols Institute
Diagnostics, San Juan Capistrano, CA) at the time of blood collection.
The overall coefficient of variation was less than 15%, and the assay
sensitivity was 0.1 g/liter. IL-6 was measured in duplicate by ELISA
(High Sensitivity Quantikine kit, R&D Systems, Inc., Minneapolis, MN)
from the frozen specimens. The lower detection limit was 0.1 pg/ml, and
the interassay coefficient of variation was 7%.
Assessment of functional outcomes
Physical function was assessed by self-reported disability and objec-
tive performance-based measures of lower extremity function. For the
former, participants were asked to report the level of difficulty in per-
forming specific tasks without help from another person or special
equipment. Responses were coded as none, little, some, a lot, or unable
to perform the task. Two mobility-related outcomes and two generalized
disability outcomes were determined from the physical function data.
Severe mobility disability was defined as a lot of difficulty or unable to
walk one quarter of a mile and/or to climb stairs. Severe limitation in
walking was defined as unable to walk or walking speed less than 0.4
m/sec (24, 25). Disability in activities of daily living (ADL) was defined
as a lot of difficulty or inability in at least one of four tasks (bathing,
transferring from bed to chair, using the toilet, and walking across a
small room). Severe instrumental ADL (IADL) disability was defined as
difficulty or unable to do three or more of four tasks (light housework,
preparing meals, shopping, and managing money).
Mortality follow-up
Vital status was obtained through follow-up interviews with proxies,
obituaries, and matching with the National Death Index over a 5-yr
period.
Assessment of chronic diseases and other covariates
Seventeen chronic diseases were ascertained at baseline with disease-
specific standardized algorithms (23). The algorithms used data from the
baseline interview, the nurse’s examination (including electrocardio-
gram, the ankle-brachial index, and spirometry), and the participant’s
current medication list. Medication use was determined by examination
of medication containers. Additional information was collected from
medical records, blood test results, and a questionnaire sent to each
participant’s primary care physician. Disease categories used in this
analysis were congestive heart failure, diabetes mellitus, peripheral ar-
terial disease, stroke, coronary heart disease (angina or myocardial in-
farction), chronic obstructive pulmonary disease, hip fracture, osteoar-
thritis, rheumatoid arthritis, and malignant neoplasms (excluding basal
cell cancer). Sociodemographic characteristics included age, race, edu-
cation, and smoking status. BMI (kilograms per square meter), com-
puted from objective measures, was categorized as less than 21.5, 21.5–
24.9, 25–29.9, and 30 or greater.
Statistical analysis
As we hypothesized that low IGF-I and high IL-6 levels represent
adverse risk factors, we defined cut-points at the lowest quartile of IGF-I
levels and the highest quartile of IL-6 levels as high risk groups for use
in analyses. Under this paradigm, women with high IGF-I and low IL-6
levels represent the lowest risk group, women with low IGF-I and high
IL-6 levels represent the highest risk group, and those with low IGF-I and
low IL-6 or high IGF-I and high IL-6 represent intermediate risk groups.
We selected the lowest quartile of IGF-I (74.3 g/liter) as our high risk
IGF-I group based on prior work suggesting a threshold effect for mo-
bility tasks at approximately this level (10). In addition, this level is near
the age-specific normal range for this IGF-I assay (71–290 g/liter). As
there are no commonly used age-specific normal ranges for the IL-6
assay, we used the highest quartile of IL-6 (3.7 pg/ml) as the cut-point
for defining risk groups. This is congruent with other studies in which
tertiles and quartiles of IL-6 were used to define risk categories for
outcomes in older individuals (15, 16, 18).
Baseline characteristics were compared by category of IGF-I and IL-6,
using the 2 test for binary outcomes and ANOVA for continuous
outcomes. The 2 and ANOVA tests do not specify a reference group,
and therefore are statistically significant when any group differs from
the others. The t test was used to compare mean IGF-I and IL-6 levels
by 5-yr mortality status. Kaplan-Meier analysis was used to study sur-
vival for the 4 risk categories of IGF-I and IL-6 across the 5 yr of
follow-up. The log-rank test was used to compare survival curves, with
a statistically significant result indicating that at least one of the curves
differs from the others. Logistic regression models that account for
intraperson correlation over time and interperson heterogeneity were
used to assess longitudinal associations between IGF-I/IL-6 categories
and functional outcomes (26). These models, which included all 718
women in our study population, account for cross-sectional associations
over time and are primarily driven by prevalent effects. Four models
were employed in all analyses: those with low IGF-I in the model, those
with high IL-6 in the model, those with both low IGF-I and high IL-6 in
the model, and those with low IGF-I, high IL-6, and an interaction term
in the model. The interpretation of a model with both low IGF-I and high
IL-6 that does not include an interaction term is that of the effect of one
factor, e.g. IGF-I, after accounting for the effect of the other, e.g. IL-6. This
model allows examination of the effect of IGF-I independently of IL-6
and vice versa, but does not allow for the possibility of synergy. Models
with low IGF-I, high IL-6, and an interaction term for low IGF-I and high
IL-6 allow detection of effect modification, that is, a different effect from
high IL-6 in the presence of low IGF-I compared with high IL-6 in the
presence of high IGF-I. This model is similar to using separate categories
for each of the 4 combinations of IGF-I and IL-6, and thus is displayed
in this manner in tabular form. All of the regression models included
adjustment for age, education, race, smoking status, BMI, oral estrogen
use, oral corticosteroid use, and chronic conditions (coronary heart dis-
ease, congestive heart failure, peripheral arterial disease, hip fracture,
osteoarthritis, rheumatoid arthritis, diabetes mellitus, cancer, stroke,
and chronic obstructive pulmonary disease). A nonparametric trend test
across the four IGF-I/IL-6 categories was employed to compare incident
disability in functional outcomes and mortality. Incident disability was
defined as the new onset of disability during the course of the study in
women without preexisting disability at baseline. Discrete-time Cox
proportional hazard regression models were used to compare mortality
risk across the IGF-I/IL-6 categories (27). These models were also ad-
justed for the covariates listed above. Analyses were performed using
MIXNO (28) for logistic regressions and SPLUS, version 2000 (Insightful,
Inc., Seattle, WA) for Cox proportional hazard models.
Results
Figure 1 displays a scatterplot of IGF-I and IL-6 levels in
this cohort of disabled older women. The mean IGF-I level
was 107.8 g/liter, the median was 101.3 g/liter, and the
range was 12.8–281.3 g/dl. The mean IL-6 level was 3.14
pg/ml, the median was 2.39 pg/ml, and the range was 0.4–
10.1 pg/ml. IGF-I and IL-6 levels were not linearly correlated
with each other, with a Spearman correlation coefficient of
0.011 (P  0.77). IL-6 levels were similar in the low IGF-
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I/high IL-6 and the high IGF-I/high IL-6 categories, with a
median level of 6.23 and a mean level of 6.68 in the low
IGF-I/high IL-6 category and a median level of 6.08 and a
mean level of 6.47 in the high IGF-I/high IL-6 group (P 
0.58, by t test for means).
The baseline characteristics of the study population are
summarized in Table 1. The mean age of participants was
77.6 yr (range, 65–100 yr), with age varying slightly among
the IGF-I/IL-6 categories. Educational level, race, current
smoking, BMI, estrogen use, corticosteroid use, and preva-
lence of peripheral arterial disease, diabetes, and congestive
heart failure varied by IGF-I/IL-6 category. Those in the low
IGF-I and high IL-6 category had higher percentages of mo-
bility and ADL disability at baseline than those in other
categories (P  0.05 for trend).
Women with IGF-I levels in the bottom quartile were more
likely to have walking limitation than women with IGF-I
levels in the top three quartiles [odds ratio (OR), 2.54; 95%
confidence interval (CI), 1.05–6.11; Table 2, model 1]. Those
with IL-6 levels in the top quartile were significantly more
likely to have walking limitation (OR, 4.99; CI, 1.95–12.80),
mobility disability (OR, 1.79; CI, 1.00–3.19), and severe IADL
disability (OR, 2.00; CI, 1.00–4.01) than those in the bottom
three quartiles (Table 2, model 2). In models assessing the
effects of IGF-I and IL-6 independently of each other, low
IGF-I was not significantly associated with any of the func-
tional outcomes (Table 2, model 3). However, high IL-6 was
associated with walking limitation (OR, 4.55; CI, 1.78–11.62)
and severe IADL disability (OR, 2.00; CI, 1.00–4.01) inde-
pendently of low IGF-I. Then, using models examining each
risk factor in the presence or absence of the other, women
with both risk factors simultaneously were much more likely
to be disabled than those with only one risk factor or neither
(Table 2, model 4). Women with both low IGF-I and high IL-6
were more likely to have walking limitation (OR, 10.77; CI,
1.68–69.11), mobility disability (OR, 5.14; CI, 1.85–14.25),
severe IADL disability (OR, 3.66: CI, 1.10–12.15), and ADL
disability (OR, 2.47; CI, 0.96–6.32) than their counterparts
without either of these risk factors. The ORs were smaller in
magnitude for those in the intermediate risk categories (low
IGF-I/low IL-6 or high IGF-I/high IL-6) than for those of the
high risk category (low IGF-I/high IL-6). The results of
model 4 are displayed graphically in Fig. 2.
We next examined the effects of IGF-I and IL-6 on incident
disability (Table 3). Due to a high prevalence of disability in
many tasks in this population, fewer women were available
for analyses involving incident outcomes. Nevertheless, the
incidence of new limitation in walking, mobility disability,
and ADL disability over a 3-yr period was greatest in the low
FIG. 1. Scatterplot showing the relationship between IGF-I and
IL-6 serum levels in the study population. The upper left quadrant
(shaded) identifies participants in the highest risk group, and the
lower right quadrant shows those in the lowest risk group. A smooth
spline (solid line) with 4 degrees of freedom is displayed, which reveals
no systematic trend.
TABLE 1. Demographic and health-related characteristics by category of IGF-I and IL-6
High IGF-I and
low IL-6 (n  398)
Low IGF-I and
low IL-6 (n  142)
High IGF-I and
high IL-6 (n  128)
Low IGF-I and
high IL-6 (n  50)
Overall
(n  718) P
a
Age (yr) 76.7 (7.7) 79.9 (8.0) 77.9 (7.6) 78.2 (8.0) 77.6 (7.9) 0.01
Education (yr) 10.0 (3.7) 9.5 (3.8) 9.6 (3.7) 8.6 (2.9) 9.7 (3.7) 0.03
Black (%) 25.6 26.1 39.0 36.0 28.9 0.02
Current smoking (%) 11.1 4.9 18.0 22.0 12.0 0.01
BMI (kg/m2) 28.8 27.2 29.9 29.1 28.8 0.01
Oral estrogen use (%) 5.8 16.2 3.1 10.0 7.7 0.01
Oral corticosteroid use (%) 3.8 3.5 10.2 2.0 4.7 0.02
Chronic diseases (%)
Osteoarthritis 57.0 52.8 53.1 54.0 55.3 0.77
CHD 31.9 31.0 34.4 26.0 31.8 0.75
PAD 16.6 17.6 32.8 22.0 20.1 0.001
Diabetes 14.6 7.7 25.8 22.0 15.7 0.001
COPD 13.6 16.2 16.4 20.0 15.0 0.58
Cancer 11.1 11.3 10.9 18.0 11.6 0.53
CHF 8.8 7.7 12.5 22.0 10.2 0.02
Hip fracture 6.5 12.0 4.7 8.0 7.4 0.10
Stroke 5.8 4.9 5.5 8.0 5.7 0.88
Rheumatoid arthritis 2.3 2.8 4.7 6.0 3.1 0.32
Mobility disability (%) 44.9 45.0 50.8 65.3 47.4 0.04
ADL disability (%) 68.8 72.5 77.3 82.0 72.0 0.02
High IGF-I refers to IGF-I in the top 75% of the distribution of levels in WHAS (74.3 g/liter), low IGF-I to the bottom 25% (74.3 g/liter).
Low IL-6 refers to the bottom 75% of the distribution of levels in WHAS (3.7 pg/ml), high IL-6 to the top 25% (3.7 pg/ml).
a P value from 2 test for binary variables and ANOVA for continuous variables.
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IGF-I/high IL-6 group (P  0.11, 0.001, and 0.09, respec-
tively, for trend).
After 5 yr, 195 of 718 women had died. The Kaplan-Meier
survival functions over the 5-yr period, stratified by category
of IGF-I and IL-6, are shown in Fig. 3. Overall, there was a
large difference in mortality between women with low and
high IL-6 levels. In addition, within each group of IL-6 levels,
those with low IGF-I levels tended to have higher mortality.
At 5 yr, 46% of the low IGF-I/high IL-6 group were dead
compared with 23% of the high IGF-I/low IL-6 group (Table
3). The mean baseline IGF-I level in those who survived for
5 yr was 110.1 g/dl vs. 101.5 g/dl for those who died
within the 5-yr period (P  0.03). The mean baseline IL-6
level for those who survived for 5 yr was 2.9 pg/ml vs. 3.8
pg/ml for those who did not (P  0.01). In multivariate Cox
proportional hazard models, high IL-6 was an independent
predictor of mortality [relative risk (RR), 1.60; 95% CI, 1.17–
2.19], whereas low IGF-I was not (RR, 1.29; CI, 0.94–1.78).
However, the low IGF-I/high IL-6 group demonstrated the
highest mortality risk of any of the IGF-I/IL-6 categories,
with a 2-fold higher risk of mortality over a 5-yr period (RR,
2.10; CI, 1.29–3.41) than the reference group with high IGF-
I/low IL-6.
Discussion
We report a combined effect of low IGF-I and high IL-6 in
predicting mobility disability, walking limitation, ADL dis-
ability, severe IADL disability, and mortality in a cohort of
disabled, community-dwelling older women. Other studies
have shown independent effects of IGF-I and IL-6 on dis-
ability and mortality (10, 14–18). To our knowledge, we are
the first to note a combined effect of circulating hormones
and inflammatory markers on important health outcomes in
an older population. Our findings provide evidence bridging
two systems that undergo significant alterations with aging.
Our results suggest two interpretations: either that IGF-I
and IL-6 are mediators of debilitating processes or that they
are markers of poor health without any pathogenic effects of
their own. Potential mechanisms for mediation effects from
low levels of IGF-I include detrimental effects on muscle,
bone, cardiac function, and cognition (29). As a proinflam-
matory cytokine, IL-6 has been implicated in the pathogen-
esis of muscle wasting, as well as of atherosclerosis, type 2
diabetes, osteoporosis, anemia, Alzheimer’s disease, depres-
sion, rheumatological disease, and lymphoproliferative dis-
orders (13, 18, 30–32). If IGF-I and IL-6 are biomediators, then
interventions to raise IGF-I and lower IL-6 would be expected
to result in beneficial effects on the clinical status of this
group of patients that is at high risk for adverse and costly
outcomes.
Substantial evidence in model systems and in humans
suggests a mechanistic link between IGF-I and IL-6. In trans-
genic mice that overexpress IL-6, low levels of IGF-I are
found relative to wild-type mice (19). Treatment of these
transgenic mice with an IL-6 antibody or with an IL-6 re-
ceptor antagonist results in normalization of IGF-I levels (19,
33). Furthermore, treatment of wild-type mice with IL-6 re-
sults in lowering of IGF-I levels (19). In rat liver cells, the
addition of IL-6 results in reduced IGF-I biosynthesis (34).
Low IGF-I levels and stunted growth have been reported in
inflammatory conditions that have high IL-6, such as sys-
temic juvenile idiopathic arthritis (19). The lower IGF-I levels
may be secondary to increased clearance of IGF-I in patients
with this condition (35).
Additionally, low levels of IGF-I may induce IL-6 expres-
sion. A human model exists, that of patients with pituitary
insufficiency who have GH deficiency. Adults with panhy-
popituitarism who are sufficiently replaced for all pituitary
hormones except GH have been shown to have high levels
of IL-6 (36). GH replacement therapy decreases serum IL-6
levels and IL-6 production by monocytes in these patients
(20, 21). Additional support for a biological relationship be-
tween the GH/IGF-I pathway and cytokines is the finding
that the GH receptor is a member of the cytokine-hemopoi-
etin superfamily (37).
It could therefore be postulated that in some individuals,
high IL-6 levels and low IGF-I levels could drive a vicious
cycle, in which these levels are each driven to extremes. Why,
then, are there individuals who have high IL-6 yet high IGF-I,
and low IGF-I yet low IL-6? A possible explanation is that
there are transient conditions that can produce high IL-6,
such as infectious illnesses, that are not captured by our data.
Other factors not examined, including other cytokines, cor-
tisol, estrogens, and androgens, may also affect IL-6 produc-
TABLE 2. Odds ratios of functional outcomes according to baseline levels of IGF-I and IL-6
Model 1 Model 2 Model 3 Model 4
































































Model 1, Low IGF-I  covariates; model 2, high IL-6  covariates; model 3, low IGF-I, high IL-6  covariates; model 4, low IGF-I, high IL-6,
interaction term for low IGF-I and high IL-6  covariates. Covariate adjustment for all models includes age at first blood draw, education, race,
smoking status, BMI, estrogen use, corticosteroid use, chronic conditions including CHD, CHF, PAD, hip fracture, OA hip and knee, RA, DM,
cancer, stroke, COPD. High IGF-I refers to IGF-I in the top 75% of the distribution of levels in WHAS, low IGF-I to the bottom 25%. Low IL-6
refers to the bottom 75% of the distribution of levels in WHAS, high IL-6 to the top 25%.
a P  0.05 vs. referent group.
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tion (13). Likewise, multiple other factors may influence
IGF-I levels besides GH status, including nutrition, exercise,
and liver function (16, 38–40). Alternatively, some individ-
uals predestined to become frail may be more susceptible to
entry into this vicious cycle than others.
When the magnitude of an effect from two risk factors
exceeds that which would be expected from merely com-
bining their individual effects, synergy is present. The mag-
nitudes of the effects seen in our high risk group suggest such
synergy between IGF-I and IL-6. Biologically, this would
mean that older women who have one risk factor (e.g. high
IL-6) are at unexpectedly increased susceptibility to adverse
events once they accumulate a second adverse risk factor (e.g.
low IGF-I). In the presence of synergy, an intervention would
need to target both risk factors to be maximally effective.
An alternative explanation is that IGF-I and IL-6 are not
mediators of biological effects, but, rather, are markers for
other processes. For example, IGF-I may be a marker of
nutritional status or of other hormonal deficiencies. Levels of
IGFBP-3, the major binding protein of IGF-I, are not available
in our cohort. Conflicting reports exist regarding the impact
that measurement of IGFBP-3 would have had on our results.
It has been reported that both IGF-I and IGFBP-3 decline with
age, although in one report the free IGF-I level was increased
in those above 70 yr (41), whereas in another the molar ratio
of IGF-I to IGFBP-3 decreased with increasing age (42). IL-6
may be a marker for another biologically important mediator
that is activated by the same process that stimulates IL-6
production. We adjusted for multiple potential confounders,
including age, BMI, smoking, relevant medications, and cer-
tain chronic diseases, in an attempt to demonstrate a risk
category independent of a specific disease state. Even if IGF-I
and IL-6 are not directly in the causal pathway to disability
and mortality, they have potential clinical utility in the iden-
tification of patients at high risk for these outcomes. It is often
difficult to assess the clinical impact or severity of one or
multiple conditions in an individual. Because multiple fac-
tors may lower IGF-I or raise IL-6, they may represent mea-
sures of global disease burden that identify the activation of
detrimental pathways better than assessments of individual
organ function.
WHAS I, as a cohort designed to represent the one third
most disabled women living in the community, is comprised
of women who represent the ideal group in which to examine
the physiological dynamics underlying disability. The use of
sampling from the Health Care Financing Administration
database instead of a volunteer recruitment mechanism,
home visits instead of travel to a study clinic, and visits every
6 months enabled us to enroll and closely follow a repre-
sentative sample of women who ordinarily exclude them-
FIG. 2. Adjusted OR of functional outcomes according to baseline levels of IGF-I and IL-6. High IGF-I refers to the top 75% of study levels;
low IGF-I refers to the bottom 25%. Low IL-6 refers to the bottom 75% of study levels; high IL-6 refers to the top 25%. Referent, High IGF-I
and low IL-6. *, P  0.05 vs. referent group.
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selves or are excluded from research studies. Our cohort was
large enough to achieve sufficient power to assess for joint
effects. However, it is possible that our results are specific to
frail older women and will not be generalizable to healthy
older individuals or to men. In addition, precise threshold
points cannot be determined from this study, although these
data support the establishment of a lower limit for IGF-I and
an upper limit for IL-6 that are linked to clinically significant
outcomes in older individuals: disability and death. Al-
though our findings support the hypothesis that those with
low IGF-I and high IL-6 represent a high risk group for
clinically meaningful adverse events, we have not elucidated
specific targets through which IGF-I and IL-6 might mediate
their effects. Additional studies are required to distinguish
potential pathways, such as via muscle or cognition.
In conclusion, our work represents an initial step toward
construction of a biological model for understanding how
pathophysiological changes in the endocrine and inflamma-
tory systems may have detrimental effects on health out-
comes of aging. Further work is required to validate and
extend our findings, so that appropriate target groups may
be defined for interventions to prevent the progression of
disabling conditions in older people.
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